Download Uses Of Epoetin For Anemia In Oncology full books in PDF, epub, and Kindle. Read online Uses Of Epoetin For Anemia In Oncology ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
Author :
Publisher :
ISBN 13 :
Total Pages : 352 pages
Book Rating : 4.45/5 ( download)
Download or read book Uses of Epoetin for Anemia in Oncology written by and published by . This book was released on 2001 with total page 352 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Uses of epoetin for anemia in oncology written by and published by . This book was released on 2001 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt:
Author : Mohammad Resa Nowrousian
Publisher : Springer Science & Business Media
ISBN 13 : 3709176581
Total Pages : 524 pages
Book Rating : 4.80/5 ( download)
Download or read book Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology written by Mohammad Resa Nowrousian and published by Springer Science & Business Media. This book was released on 2012-12-06 with total page 524 pages. Available in PDF, EPUB and Kindle. Book excerpt: Anemia is a frequent complication of cancer and its treatment. A number of clinical studies shows that the impact of anemia is much greater than previously thought. Beyond clinical symptoms, anemia significantly impairs physical and metabolic functions as well as patients' activity, well-being and quality of life. Life expectancy is also affected. In this book, written by a group of outstanding international experts, the current knowledge on anemia in cancer and its treatment with rhEPO is presented. Future developments are also discussed. Based on a broad spectrum of topics, the book describes the scientific and clinical aspects of anemia in various fields of oncology and gives diagnostic and therapeutic recommendations on when and how to use rhEPO.
Author : Carsten Bokemeyer
Publisher : Elsevier Science Health Science Division
ISBN 13 : 9780080445755
Total Pages : 304 pages
Book Rating : 4.56/5 ( download)
Download or read book Anaemia in Cancer written by Carsten Bokemeyer and published by Elsevier Science Health Science Division. This book was released on 2004-11 with total page 304 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Author : U. S. Department of Health and Human Services
Publisher : CreateSpace
ISBN 13 : 9781490528267
Total Pages : 272 pages
Book Rating : 4.61/5 ( download)
Download or read book Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment: Comparative Effectiveness Update written by U. S. Department of Health and Human Services and published by CreateSpace. This book was released on 2013-06-24 with total page 272 pages. Available in PDF, EPUB and Kindle. Book excerpt: Anemia, a deficiency in the concentration of hemoglobin-containing red blood cells, is prevalent among cancer patients, depending on the type of malignancy and treatment. Transfusion is one option for treating anemia related to cancer and cancer treatment. Transfusion carries a very low risk of infection and other adverse events, including transfusion reactions, alloimmunization, overtransfusion, and immune modulation with theoretically possible adverse effects on tumor growth. (For example, adverse events that could be definitively attributed to transfusions were not reported in any trial included in this review for adverse event outcomes.) Erythropoietin, a hormone produced in the kidney, is the major regulator of red blood cell production (erythropoiesis). Commercially produced recombinant human erythropoietins have been extensively studied and used clinically for more than a decade to treat anemia in association with various diseases, reducing the need for transfusion. These include epoetin alfa (Epogen®, Procrit®) and epoetin beta (not available in the United States); they have similar clinical efficacy. Darbepoetin alfa (Aranesp®), more recently developed, produces a similar physiologic response and is commercially available in the United States. All erythropoietic-stimulating agents (ESAs) increase the number of red blood cells within about 2 to 3 weeks when given to individuals with functioning erythropoiesis. The development of intensified antineoplastic therapies has increased the risk for anemia and the likelihood of treatment. Initially, adverse effects that could be conclusively attributed to erythropoietin treatment had been reported in very few patients; more recently, randomized controlled trials have reported increased incidence of thrombotic events and reduced survival. This resulted in multiple pooled analyses of ESA trial data over several years, as well as regulatory actions by the U.S. Food and Drug Administration (FDA). The Blue Cross and Blue Shield Association Technology Evaluation Center, an Evidence-based Practice Center funded by the Agency for Healthcare Research and Quality, conducted a systematic review of epoetin use in oncology (2001) and a comparative effectiveness review, “Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment” (2006). This update includes new evidence that was not available in 2006. In particular, we incorporated results from a recently published meta-analysis3 of individual patient data from studies enrolling more than 50 patients per arm; inclusion for this update was limited to studies of similar size. In contrast, the previous report2 included studies enrolling 10 or more patients per arm. Sensitivity analyses performed for each outcome with data from studies excluded because of size showed no differing results. This report addresses the following Key Questions: Key Question 1. What are the comparative benefits and harms of erythropoiesis-stimulating agent strategies and non-ESA strategies to manage anemia in patients undergoing chemotherapy or radiation for malignancy (excluding myelodysplastic syndrome and acute leukemia)? Key Question 2. How do alternative thresholds for initiating treatment compare regarding their effect on the benefits and harms of erythropoietic stimulants? Key Question 3. How do different criteria for discontinuing therapy or for optimal duration of therapy compare regarding their effect on the benefits and harms of erythropoietic stimulants?
Author : U. S. Department of Health and Human Services
Publisher : Createspace Independent Pub
ISBN 13 : 9781490386430
Total Pages : 394 pages
Book Rating : 4.32/5 ( download)
Download or read book Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment written by U. S. Department of Health and Human Services and published by Createspace Independent Pub. This book was released on 2013-06-07 with total page 394 pages. Available in PDF, EPUB and Kindle. Book excerpt: This review compares the efficacy and adverse effects of specific erythropoietic stimulants (i.e., epoetin [alfa or beta], darbepoetin alfa) when used to manage anemia in patients undergoing cancer therapy (i.e., chemotherapy and/or radiation). This review also addresses questions relevant to optimizing the use of erythropoietic stimulants as a general class: the outcomes of using alternative thresholds to initiate or discontinue treatment and whether there are early predictors of response to treatment. Erythropoietin is an endogenous hormone, produced primarily in the kidney, which participates in regulating red blood cell production (erythropoiesis). Two forms of recombinant human erythropoietin—epoetin alfa and epoetin beta (the latter not commercially available in the United States)—have been extensively studied and used clinically for more than a decade to treat various anemias; they have similar clinical efficacy. In a recent review of safety concerns associated with recombinant human erythropoietins, a U.S. Food and Drug Administration (FDA) briefing document noted that “…the biochemical differences between various erythropoietin products are not associated with marked differences in the pharmacodynamic properties of the different products when used at recommended doses, thus effects observed with these non-US-licensed products may also be associated with the U.S. licensed product.” Anemia (deficiency of red blood cells) occurs in 13-78 percent of patients undergoing treatment for solid tumors and 30-40 percent of patients treated for lymphoma. Tumor type, treatment regimen, and history of prior cancer therapy influence the risk and severity of anemia. This report focuses on use of epoetin or darbepoetin to manage anemia in patients undergoing cancer treatment with chemotherapy and/or radiation. Anemia severity is defined by hemoglobin (Hb) concentration. Erythropoietin, a hormone produced primarily in the kidney, participates in regulating red blood cell production (erythropoiesis) and thus Hb concentration. Two erythropoietic stimulants are available commercially in the United States, epoetin alfa (Epogen®, Procrit®) and darbepoetin alfa (Aranesp®), which is a newer and longer acting drug. Epoetin beta, which is pharmacologically and clinically similar to epoetin alfa, is commercially available in Europe and elsewhere. Erythropoietic stimulants are widely used in clinical practice to manage anemia of patients undergoing cancer treatment and to reduce the need for transfusion. Although it is well established that erythropoietic stimulants improve anemia in patients undergoing cancer treatment, the comparative effectiveness of epoetin and darbepoetin has not been evaluated in a systematic review. Moreover, trials varied substantially in how erythropoietic stimulants have been used, including Hb concentration at start of treatment, doses given, treatment duration, and target Hb concentrations they sought to maintain. A review of these various trials may help maximize benefit, optimize drug usage, and minimize adverse effects from using erythropoietic stimulants to manage anemia in patients undergoing cancer treatment. The report addresses the following questions: 1. What are the comparative efficacy and safety of epoetin (alfa or beta) and darbepoetin? 2. How do alternative dosing strategies affect the comparative efficacy and safety of epoetin and darbepoetin? 3. How do alternative thresholds for initiating treatment or alternative criteria for discontinuing therapy or duration of therapy affect the efficacy and safety of erythropoietic stimulants? 4. Are any patient characteristics at baseline or early hematologic changes useful to select patients or predict responses to treatment with erythropoietic stimulants?
Author : Horst Pagel
Publisher : Springer Science & Business Media
ISBN 13 : 3642770746
Total Pages : 318 pages
Book Rating : 4.46/5 ( download)
Download or read book Pathophysiology and Pharmacology of Erythropoietin written by Horst Pagel and published by Springer Science & Business Media. This book was released on 2012-12-06 with total page 318 pages. Available in PDF, EPUB and Kindle. Book excerpt: The book contains a series of about 40 articles reflecting the state-of-the-art of the topic "Pathophysiology and Pharmacology of Erythropoietin". Results from both basic research and clinical studies are described in detail. The papers show that the possible therapeutic spectrum of erythropoietin could be expanded considerably when compared with the present situation.
Author : Carsten Bokemeyer
Publisher : Elsevier Science Health Science Division
ISBN 13 : 9780444509048
Total Pages : 227 pages
Book Rating : 4.46/5 ( download)
Download or read book Anaemia in Cancer written by Carsten Bokemeyer and published by Elsevier Science Health Science Division. This book was released on 2001 with total page 227 pages. Available in PDF, EPUB and Kindle. Book excerpt: This volume provides a comprehensive, state-of-the-art overview of the pathogenesis, treatment and treatment effects of chronic anaemia of cancer as well as chemotherapy- and radiotherapy-induced anaemia. It is the result of a joint effort by the members of the European School of Oncology (ESO) Task Force on Anaemia in Cancer and the participants of an ESO Symposium on this topic. negative prognostic factor for clinical outcome in cancer patients. In addition, there is evidence that tissue hypoxia contributes to the progression of malignant disease by inducing a more malignant phenotype, stimulating angiogenesis within tumour tissues, and diminishing the sensitivity of tumour cells to chemotherapy and radiation therapy. traditional treatment for anaemia - the transfusion of red blood cells - has significant limitations. This situation has changed dramatically with the introduction of recombinant human erythropoietin, which acts as an important physiological stimulator of human erythropoiesis. The beneficial effects of erythropoietin markedly exceed those of transfusions. Erythropoietin can lead to complete, long-term normalization of anaemia which in turn results in a significant improvement in anaemic cancer patients' quality of life and physical exercise capacity.
Author :
Publisher :
ISBN 13 :
Total Pages : 112 pages
Book Rating : 4.65/5 ( download)
Download or read book Recombinant Erythropoietin written by and published by . This book was released on 1990 with total page 112 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Author :
Publisher : Springer
ISBN 13 : 9783642588143
Total Pages : 252 pages
Book Rating : 4.4X/5 ( download)
Download or read book Blood Perfusion and Microenvironment of Human Tumors written by and published by Springer. This book was released on 2012-11-26 with total page 252 pages. Available in PDF, EPUB and Kindle. Book excerpt:
